-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 9, the Center for Drug Evaluation (CDE) of the State Drug Administration officially granted Boehringer Ingelheim the first-in-class immunology drug spesolimab (the company's own generic name: spesolimab injection) with priority review and approval Eligibility, the proposed indication is for the treatment of adults with generalized pustular psoriasis (GPP) episodes
Priority review is set up by the Center for Drug Evaluation (CDE) of the State Drug Administration to encourage the research and creation of new drugs, meet clinical drug needs, and speed up the review of innovative drugs
Unlike plaque psoriasis, GPP is a rare but more serious skin disease
In recent years, studies have found that pustular psoriasis is associated with the interleukin-36 (IL-36) pathway
About spesolimab
About spesolimabSpesolimab is a novel humanized selective antibody that blocks activation of the interleukin-36 receptor (IL-36R)
references:
[1] "Survey on the prevalence and disease burden of generalized pustular psoriasis in my country: an estimate based on the national urban medical insurance data from 2012 to 2016", the 27th National Dermatological Diseases of the Chinese Medical Association Academic Annual Meeting, June 2021
[2] Furue K, et al.
[3] Bachelez H, et al.
[4] ClinicalTrials.
[5] ClinicalTrials.
(Original abridged)
